ASCO (58)

Long-term immune-related adverse events frequent after PD-1 inhibitor use in patients with melanoma

Long-term immune-related adverse events (IRAE) are frequent in patients with melanoma treated with PD-1 inhibitors (anti-PD1), especially when IRAEs have previously occurred, according to a presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In 119 patients with advanced melanoma who had received anti-PD1 monotherapy at...